Medication info
Tubica Tablets 5/20 Milligrams

Tubica Tablets 5/20 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Geonil Biopharm Co., Ltd.
Appearance
White round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201903519 · Approved 2019.05.29 · Insurance code 073000020

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Geonil Biopharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension when adequate blood pressure control is not achieved with monotherapy of amlodipine or olmesartan medoxomil. In this case, it helps to more effectively control blood pressure with combination therapy and reduce the risk of complications due to hypertension. It contributes to the prevention of cardiovascular diseases through safe and effective blood pressure management.

How to take

Adult dose

Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Persons who are allergic to this drug's active ingredients or dihydropyridine derivatives, those who are pregnant or breastfeeding, patients with severe liver dysfunction, aortic stenosis, bile duct obstruction, those undergoing kidney dialysis, patients in shock, and certain diabetic patients should not take this medication. Patients with hypotension due to fluid or salt depletion, patients with severe vascular dilation, severe obstructive coronary artery disease, congestive heart failure, kidney impairment, and liver impairment should be closely monitored while taking this medication. While taking this medication, adverse reactions such as dizziness, headache, hypotension, palpitations, dyspepsia, rash, and edema may occur, and if symptoms are severe, a consultation with medical personnel is advised. Unlike when abruptly stopping beta-blockers, while this drug is not a beta-blocker, the dose should be tapered slowly if discontinuing beta-blocker therapy. There may be interactions when taken with other antihypertensives, diuretics, antibiotics, or grapefruit juice, so all medications being taken should be reported to medical personnel. This medication should not be taken during pregnancy, and if planning to become pregnant, it is advisable to switch to other treatments with proven safety instead of this medication. During breastfeeding, this medication may be passed into breast milk and cause adverse reactions in infants, so it is recommended to either stop breastfeeding or discontinue this medication. This medication is not recommended for patients under 18 years of age, as safety and efficacy have not been established. Elderly patients may have decreased kidney and liver function, so the dose should be carefully adjusted, and attention to adverse effects is necessary. In the event of an overdose, symptoms such as hypotension and increased heart rate may occur, so if suspected, immediate medical attention is necessary. This medication should be stored out of the reach of children, in a tightly sealed container to prevent exposure to air or moisture, and should be kept away from direct sunlight, humidity, and heat; it is also safe not to transfer to another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • reduced sensation
  • syncope
Show 86 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • vascular edema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • increased serum potassium
  • low back pain
  • bronchitis
  • increased creatine phosphokinase
  • hematuria
  • hyperglycemia
  • hypertriglyceridemia
  • influenza-like symptoms
  • pharyngitis
  • rhinitis
  • sinusitis
  • urticaria
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • marked peripheral vasodilation
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, it is advisable to store the medication at room temperature between 1 to 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.